Literature DB >> 20640940

The cardinal features of recurrent autoimmunity in simultaneous pancreas-kidney transplant recipients.

Boaz Hirshberg1.   

Abstract

Entities:  

Year:  2010        PMID： 20640940     DOI： 10.1007/s11892-010-0134-2

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  7 in total

Review 1.  Pancreas transplantation.

Authors:  Steve A White; James A Shaw; David E R Sutherland
Journal:  Lancet       Date:  2009-05-23       Impact factor: 79.321

2.  Survival after pancreas transplantation in patients with diabetes and preserved kidney function.

Authors:  Jeffrey M Venstrom; Maureen A McBride; Kristina I Rother; Boaz Hirshberg; Trevor J Orchard; David M Harlan
Journal:  JAMA       Date:  2003-12-03       Impact factor: 56.272

3.  Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes.

Authors:  George S Eisenbarth
Journal:  Diabetes       Date:  2010-04       Impact factor: 9.461

4.  Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience.

Authors:  Boaz Hirshberg; Kristina I Rother; Benigno J Digon; Janet Lee; Jason L Gaglia; Kenneth Hines; Elizabeth J Read; Richard Chang; Bradford J Wood; David M Harlan
Journal:  Diabetes Care       Date:  2003-12       Impact factor: 19.112

5.  Recurrence of disease in pancreas transplants.

Authors:  D E Sutherland; F C Goetz; R K Sibley
Journal:  Diabetes       Date:  1989-01       Impact factor: 9.461

6.  Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft.

Authors:  E H Liu; B J Digon; B Hirshberg; R Chang; B J Wood; Z Neeman; A Kam; R A Wesley; S M Polly; R M Hofmann; K I Rother; D M Harlan
Journal:  Diabetologia       Date:  2009-05-06       Impact factor: 10.122

7.  A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.

Authors:  Kevan C Herold; Stephen E Gitelman; Umesh Masharani; William Hagopian; Brygida Bisikirska; David Donaldson; Kristina Rother; Beverly Diamond; David M Harlan; Jeffrey A Bluestone
Journal:  Diabetes       Date:  2005-06       Impact factor: 9.461
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.